Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    10,987 result(s) found. Displaying page 273 of 550.
    «« First « Previous 269  270  271  272  273  274  275  276  277  Next» Last»»
    EudraCT Number: 2006-003107-39 Sponsor Protocol Number: 0524A-023 Start Date*: Information not available in EudraCT
    Sponsor Name:Merck & Co
    Full Title: A Worldwide, Multicenter, Double-Blind, Randomized, Parallel Study to Evaluate the Efficacy of MK-0524 to Improve Tolerability of Extended Release Niacin
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001472-20 Sponsor Protocol Number: LEO19123-C21 Start Date*: 2006-08-15
    Sponsor Name:LEO Pharma A/S
    Full Title: LEO19123 Cream in the Treatment of Atopic Dermatitis A Phase II, proof of concept study, testing once daily use of two dose-combinations of LEO19123 cream (calcipotriol and LEO80122) in the treatm...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed) FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004303-19 Sponsor Protocol Number: BSX - 001 Start Date*: 2007-04-25
    Sponsor Name:Cerimon Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulc...
    Medical condition: Steroid-refractory ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009900 Colitis ulcerative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) CZ (Prematurely Ended) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001859-35 Sponsor Protocol Number: cro632 Start Date*: 2007-04-13
    Sponsor Name:Imperial College London
    Full Title: Abatacept in ANCA associated vasculitis: ABAVAS
    Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000042-12 Sponsor Protocol Number: A7881004 Start Date*: 2007-06-05
    Sponsor Name:Pfizer Ltd. Ramsgate Road, Sandwich, Kent, UK
    Full Title: A PHASE IIA RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE CONTROLLED 5-WAY CROSS-OVER TRIAL TO EXAMINE THE BRONCHODILATOR EFFECTS OF PF-610,355 AND TO TEST FOR SUPERIORITY VERSUS PLACE...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002145-21 Sponsor Protocol Number: 2007003 Start Date*: 2007-12-21
    Sponsor Name:Procter & Gamble Pharmaceuticals
    Full Title: A Phase II, Randomized, Placebo-controlled Study of ATI-7505 in Patients with Chronic Idiopathic Constipation
    Medical condition: Chronic Idiopathic Constipation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063582 Constipation chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003997-24 Sponsor Protocol Number: LTS 6047 Start Date*: 2008-07-08
    Sponsor Name:Sanofi-Aventis recherche & développement
    Full Title: Long-term extension of the multinational, double-blind, placebo controlled study PDY6045 and PDY6046 to document the safety of teriflunomide when added to treatment with interferon-beta or glatiram...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006276-11 Sponsor Protocol Number: VR496/005 Start Date*: 2008-09-01
    Sponsor Name:Vectura Limited
    Full Title: A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cys...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004888-22 Sponsor Protocol Number: CHCD122A2103 Start Date*: 2008-03-27
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed...
    Medical condition: Advanced non Hodgkin's or Hodgkin's lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-007000-15 Sponsor Protocol Number: CICL670A2209 Start Date*: 2009-01-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, phase II study to evaluate efficacy and safety of deferasirox in nontransfusion-dependent thalassemia patients with iron overload (THALASSA)
    Medical condition: Chronic iron overload in patients with non-transfusion-dependent thalassemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043389 Thalassaemic disorders HLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-002096-27 Sponsor Protocol Number: CFTY720D2309 Start Date*: 2008-09-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month double-blind, randomized, multicenter, placebocontrolled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ...
    Medical condition: Relapsing-remitting multiple sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed) AT (Completed) LT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001413-14 Sponsor Protocol Number: 205.416 Start Date*: 2008-08-20
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 ...
    Medical condition: Patients with severe persistent asthma who are still symptomatic despite being treated with high-dose inhaled corticosteroids and long-acting beta2-agonists. Additional asthma treatments are allowe...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049106 Asthma chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000349-68 Sponsor Protocol Number: B0451004 Start Date*: 2008-11-05
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York NY10017
    Full Title: A PHASE II PROSPECTIVE, RANDOMIZED, MULTI-CENTER, DIABETIC MACULAR EDEMA DOSE RANGING, COMPARATOR STUDY EVALUATING THE EFFICACY AND SAFETY OF PF-04523655 VERSUS LASER THERAPY (DEGAS)
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006545-41 Sponsor Protocol Number: PPD/2007/AER 001 DPI/2b Start Date*: 2009-03-20
    Sponsor Name:Aerovance, Inc
    Full Title: A PHASE IIB STUDY TO INVESTIGATE THE TREATMENT-SPARING EFFECTS OF AEROVANT™ (AER 001 INHALATION POWDER) IN ASTHMA PATIENTS NOT FULLY CONTROLLED ON CURRENT THERAPY
    Medical condition: moderate persistent to severe persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006252-21 Sponsor Protocol Number: 3160A6-2207-WW Start Date*: 2009-05-28
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc
    Full Title: A Phase 2, Randomized, Open-label Study of Bosutinib Administered in Combination With Letrozole Versus Letrozole Alone as First Line Therapy in Post-Menopausal Women With Locally Advanced or Metast...
    Medical condition: Locally advanced or metastatic ER+/PgR+/erbB2-breast cancer in post-menopausal women
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) BE (Completed) GB (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015386-30 Sponsor Protocol Number: GLP108486 Start Date*: 2010-01-29
    Sponsor Name:GlaxoSmithKline LLC
    Full Title: A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005100-41 Sponsor Protocol Number: IB1001-01 Start Date*: 2009-03-16
    Sponsor Name:Aptevo Europe Limited
    Full Title: Phase I/II/III Pharmacokinetic and Outcome Study of Recombinant Factor IX Product, IB1001, in Subjects with Haemophilia B
    Medical condition: Haemophilia B
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10060614 Hemophilia B (Factor IX) LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) FR (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010425-39 Sponsor Protocol Number: KF5503/43 Start Date*: 2009-09-23
    Sponsor Name:Grünenthal GmbH
    Full Title: An evaluation of the effectiveness and tolerability of tapentadol hydrochloride prolonged release, and tapentadol hydrochloride immediate release on demand, in subjects with severe chronic pain due...
    Medical condition: Pain due to Osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031161 Osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-011672-29 Sponsor Protocol Number: NN1250-3585 Start Date*: 2009-11-25
    Sponsor Name:Novo Nordisk A/S
    Full Title: A trial investigating the efficacy and safety of NN1250 compared to insulin detemir in subjects with type 1 diabetes mellitus in a basal/bolus treatment regimen
    Medical condition: type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012283-14 Sponsor Protocol Number: SECOND-LINE Start Date*: 2010-08-16
    Sponsor Name:National Centre in HIV Epidemiology and Clinical Research
    Full Title: A randomised open‐label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2‐3N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virological...
    Medical condition: Chronic HIV infection
    Disease: Version SOC Term Classification Code Term Level
    12.0 10008919 Chronic HIV infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed) FR (Ongoing) GB (Completed) DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 269  270  271  272  273  274  275  276  277  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Feb 15 13:02:45 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA